Ep. 385 - MFN deals, Lilly takeout, FDA pick Overton

Mid-sized biopharma companies are under growing pressure to accept most-favored nation drug pricing deals with the White House. On the latest BioCentury This Week podcast, BioCentury's analysts assess the trade-offs companies face, the litigation risks around mandatory Medicare MFN pricing demonstrations, and what happens to companies that don't sign on.The analysts also discuss Eli Lilly's acquisition of Merida, its thirteenth takeout of the year, Heidi Overton's nomination as FDA commissioner and what it signals about FDA independence, and Revolution Medicines' 35-day filing-to-approval timeline under FDA's national priority review voucher pilot.View full story: https://www.biocentury.com/article/660655#DrugPricing #FDA #BiotechMA #Oncology #BiopharmaPolicy0:00 - Introduction2:14 - MFN Drug Pricing Deals10:09 - Lilly Acquires Merida22:22 - FDA Commissioner Pick30:11 - RevMed's Rapid ApprovalTo submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected] us by sending a text